Profile data is unavailable for this security.
About the company
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.
- Revenue in USD (TTM)181.41m
- Net income in USD-59.56m
- Incorporated2021
- Employees377.00
- LocationXeris Biopharma Holdings Inc1375 West Fulton Street, Suite 1300CHICAGO 60607United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.xerispharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biostem Technologies Inc | 131.44m | 7.87m | 371.35m | 67.00 | 68.14 | 20.51 | 45.94 | 2.83 | 0.3346 | 0.3346 | 7.31 | 1.11 | 2.80 | 7.41 | 3.35 | -- | 16.78 | -- | 107.11 | -- | 94.73 | -- | 5.98 | -- | 1.20 | 15.52 | 0.2012 | -- | -- | -- | -- | -- | -- | -- |
| Revance Therapeutics Inc | 247.00m | -180.81m | 385.47m | 597.00 | -- | -- | -- | 1.56 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Rigel Pharmaceuticals Inc | 130.30m | -14.23m | 388.32m | 147.00 | -- | -- | -- | 2.98 | -0.8136 | -0.8136 | 7.45 | -1.70 | 1.06 | 1.05 | 5.24 | 886,401.40 | -11.59 | -28.82 | -19.93 | -47.26 | 92.41 | 97.88 | -10.92 | -35.76 | 1.48 | -1.73 | 2.00 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Theravance Biopharma Inc | 62.02m | -45.65m | 437.36m | 99.00 | -- | 2.26 | -- | 7.05 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Esperion Therapeutics Inc | 295.45m | -86.77m | 447.39m | 240.00 | -- | -- | -- | 1.51 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 298.76m | -165.87m | 456.15m | 384.00 | -- | 1.75 | -- | 1.53 | -2.45 | -2.45 | 4.34 | 3.84 | 0.7605 | 3.69 | 15.91 | 778,026.10 | -42.22 | -- | -50.91 | -- | 84.64 | -- | -55.52 | -- | 4.66 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Zevra Therapeutics Inc | 23.99m | -65.75m | 473.56m | 65.00 | -- | 11.64 | -- | 19.74 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Aquestive Therapeutics Inc | 58.36m | -25.72m | 497.83m | 135.00 | -- | -- | -- | 8.53 | -0.3565 | -0.3565 | 0.7874 | -0.3896 | 0.6685 | 2.85 | 7.25 | 432,296.30 | -29.46 | -76.63 | -42.14 | -123.85 | 68.49 | 64.24 | -44.07 | -102.95 | 6.98 | -2.67 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Xeris Biopharma Holdings Inc | 181.41m | -59.56m | 517.03m | 377.00 | -- | -- | -- | 2.85 | -0.4215 | -0.4215 | 1.28 | -0.1295 | 0.5493 | 0.7428 | 4.99 | 481,201.60 | -18.04 | -43.60 | -23.57 | -56.57 | 83.72 | 78.23 | -32.83 | -143.08 | 1.69 | -1.59 | 1.09 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| SNDL Inc | 655.68m | -81.17m | 525.69m | 2.52k | -- | 0.5927 | -- | 0.8018 | -0.3107 | -0.3107 | 2.50 | 3.34 | 0.5988 | 4.63 | 33.15 | 260,604.80 | -7.67 | -24.44 | -8.32 | -27.94 | 25.04 | 22.49 | -12.82 | -62.17 | 2.98 | -- | 0.1125 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| SIGA Technologies Inc | 172.96m | 83.97m | 540.27m | 45.00 | 6.51 | 3.22 | 6.39 | 3.12 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Elite Pharmaceuticals Inc | 66.45m | 19.58m | 544.61m | 64.00 | 26.65 | 9.35 | 25.86 | 8.20 | 0.0191 | 0.0191 | 0.064 | 0.0545 | 0.9892 | 2.91 | 4.98 | 1,038,252.00 | 29.15 | 19.07 | 36.18 | 24.29 | 45.27 | 46.63 | 29.47 | 20.77 | 2.09 | 1.44 | 0.1389 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 599.95m | 76.00 | -- | 41.52 | -- | 261.34 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.10bn | -587.00m | 635.81m | 1.60k | -- | 1.61 | -- | 0.5769 | -11.24 | -11.24 | 21.13 | 7.30 | 0.597 | 2.39 | 4.53 | 688,875.00 | -31.80 | -2.94 | -49.34 | -3.66 | 27.18 | 53.24 | -53.26 | -5.95 | 0.5438 | -1.87 | 0.6906 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
Data as of Nov 11 2024. Currency figures normalised to Xeris Biopharma Holdings Inc's reporting currency: US Dollar USD
24.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 9.25m | 6.21% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 7.38m | 4.95% |
| Caxton Corp.as of 30 Jun 2024 | 5.11m | 3.43% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 3.26m | 2.19% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.24m | 2.18% |
| Rosalind Advisors, Inc.as of 30 Sep 2024 | 3.10m | 2.08% |
| Millennium Management LLCas of 30 Jun 2024 | 1.70m | 1.14% |
| CenterBook Partners LPas of 30 Jun 2024 | 1.47m | 0.98% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.35m | 0.91% |
| AQR Capital Management LLCas of 30 Jun 2024 | 1.19m | 0.80% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
